NBIO fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of monoclonal antibodies for the treatment of various forms of cancer. It focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Its products include Pritumumab, CLNH5, and MultiPharm. The company was founded by Mark C. Glassy on March 3, 2014 and is headquartered in North Palm Beach, FL.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
NBIO does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company